Baseline PD (mV)
|
Amiloride effect (ΔmV)
|
---|
Day
|
Control asODN
|
ENaC asODN
|
Control asODN
|
ENaC asODN
|
---|
|
Pre
|
Post
|
Pre
|
Post
|
Pre
|
Post
|
Pre
|
Post
|
---|
1
|
15.7 (1.8)
|
16.3 (1.6)
|
15.1 (1.8)
|
20.4 (2.1)
|
-14.3 (1.8)
|
-9.1 (1.3)
|
-14.6 (1.9)
|
-9.7 (1.4)
|
2
|
16.9 (2.3)
|
17.2 (1.7)
|
16.0 (1.2)
|
16.3 (2.0)
|
-15.7 (2.3)
|
-13.7 (1.6)
|
-14.8 (1.4)
|
-12.1 (1.3)
|
3
|
16.8 (1.9)
|
17.0 (1.9)
|
18.0 (1.9)
|
16.1 (0.9)
|
-12.1 (1.5)
|
-13.0 (2.0)
|
-14.8 (1.4)
|
-12.6 (1.3)
|
- n = 8–10/group. Data are expressed as mean (SEM)
- PD = nasal potential difference
- Pre = measurements at least 7 to 10 days before administration of control or ENaC asODNs
- Post = measurements at the indicated time-points after administration of control or ENaC asODNs.